Core Viewpoint - ZyVersa Therapeutics, Inc. has entered into a warrant inducement agreement with an institutional investor, which includes the immediate exercise of existing warrants and the issuance of new warrants at a reduced exercise price of $0.67, generating approximately $2.0 million in gross cash proceeds for working capital and corporate purposes [1][2]. Group 1 - The agreement involves the immediate exercise of Series A-2 Warrants for up to 957,200 shares and Series A-3 Warrants for up to 2,105,265 shares at an exercise price of $0.67 [1]. - The investor will receive new Series A-4 Warrants to purchase up to 6,124,930 shares, which will be exercisable upon stockholder approval and will expire five years from that date [2]. - The transaction is expected to close on or about July 9, 2025, pending customary closing conditions [2]. Group 2 - A.G.P./Alliance Global Partners served as the exclusive financial advisor for this transaction [3]. - The new warrants were offered in a private placement under an exemption from the registration requirements of the Securities Act, and the company plans to file a registration statement with the SEC for the resale of common stock upon exercise of the new warrants [4]. Group 3 - ZyVersa Therapeutics is a clinical stage specialty biopharmaceutical company focused on developing first-in-class drugs for renal and inflammatory diseases, utilizing proprietary technologies such as Cholesterol Efflux Mediator™ VAR 200 and Inflammasome ASC Inhibitor IC 100 [6].

Company Overview - ZyVersa Therapeutics, Inc. is a clinical stage specialty biopharmaceutical company focused on developing first-in-class drugs for renal and inflammatory diseases with significant unmet medical needs [5] - The company is advancing a therapeutic development pipeline that includes Cholesterol Efflux Mediator™ VAR 200 for kidney diseases and Inflammasome ASC Inhibitor IC 100 for inflammatory diseases [5] Share Purchase Agreement (SPA) - ZyVersa has entered into a share purchase agreement with Williamsburg Venture Holdings, allowing the company to sell up to $10 million worth of common stock over a 24-month period [3] - The SPA provides ZyVersa with flexibility in planning the timing and amount of equity sales, aiming to minimize dilution while sustaining shareholder value [2][3] - ZyVersa retains control over the timing and amount of all common stock sales, with no associated warrants or derivatives [3] Market Potential - The global drug market for kidney diseases was valued at $18 billion in 2024 and is projected to reach $30 billion by 2034 [1]

Study results corroborate our recently published data demonstrating the critical role of microglial-driven inflammation in promoting accumulation and spread of toxic phosphorylated alpha-synuclein leading to neurodegeneration in Parkinson’s Disease (PD).Our data showed that microglial inflammation was driven by activation of NLRP1 inflammasomes triggered by ASC specks and alpha-synuclein aggregates. Inflammasome ASC Inhibitor IC 100 inhibited NLRP1 inflammasome activation, thereby reducing the levels and sp ...

KEY HIGHLIGHTS First patient expected to start therapy by end of Q2-2025 in Phase 2a proof-of concept clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease (DKD).Obesity-associated cardiometabolic preclinical proof-of-concept study with Inflammasome ASC Inhibitor IC 100 planned to begin by end of Q2-2025.Investigational New Drug Application (IND) for IC 100 anticipated to be submitted H2-2025, followed by initiation of a Phase 1 clinical trial in healthy overweigh ...

WESTON, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA), a clinical-stage biopharmaceutical company specializing in first-in-class therapies for inflammatory and renal diseases, announces significant developments for Inflammasome ASC Inhibitor IC 100. CEO Stephen C. Glover issued a shareholder letter detailing the company's strategy to position IC 100 as a complementary therapy to GLP-1 agonists to treat obesity-associated cardiometabolic complications. Obesity: A Global Hea ...

Core Insights - ZyVersa Therapeutics, Inc. has announced new data supporting its Inflammasome ASC Inhibitor IC 100 as a potential treatment to slow the progression of Parkinson's disease [1][2] - The study published in npj Parkinson's Disease reveals that IC 100 blocks microglial inflammasome activation and reduces neurotoxic alpha-synuclein accumulation, both of which are critical in the progression of Parkinson's disease [2][7] Company Overview - ZyVersa is a clinical stage specialty biopharmaceutical company focused on developing first-in-class drugs for inflammatory and renal diseases, with a strong position in the inflammasome space [10] - The company is preparing to initiate proof-of-concept studies for IC 100 in animal models later this year [3] Study Findings - The research indicates that targeting inflammasomes and ASC specks may also be beneficial for treating Lewy body dementia and Alzheimer's Disease [5] - IC 100 is a humanized IgG4 monoclonal antibody designed to inhibit the inflammasome adaptor protein ASC, which plays a role in the inflammatory response [6] Market Context - Parkinson's Disease affects over 10 million people globally, with the current treatment market valued at $6.6 billion in 2024 and projected to reach $13.3 billion by 2034 [7] - Current treatments primarily address symptoms rather than the underlying disease, highlighting the potential market opportunity for disease-modifying therapies like IC 100 [7]

Core Insights - ZyVersa Therapeutics, Inc. announces promising data for its Inflammasome ASC Inhibitor IC 100, which may slow the progression of Parkinson's disease [1][3] - The study published in npj Parkinson's Disease shows that IC 100 blocks microglial inflammasome activation and reduces neurotoxic alpha-synuclein accumulation, both critical in Parkinson's disease progression [2][7] Company Overview - ZyVersa is a clinical stage specialty biopharmaceutical company focused on developing first-in-class drugs for inflammatory and renal diseases, with a significant market opportunity exceeding $100 billion [10] - The company is advancing its lead candidate IC 100, a humanized IgG4 monoclonal antibody targeting inflammasome adaptor protein ASC, which is designed to mitigate inflammatory responses [6][10] Study Findings - The research indicates that IC 100 uniquely inhibits ASC speck activity and misfolded protein aggregates, making it a strong candidate for treating neurodegenerative diseases, including Lewy body dementia and Alzheimer's Disease [5] - The study highlights the presence of ASC and NLRP1 in alpha-synuclein aggregates in neuronal Lewy bodies, suggesting a link between inflammasome activation and neurodegeneration in Parkinson's disease [8] Market Context - The global Parkinson's disease drug market was valued at $6.6 billion in 2024 and is projected to reach $13.3 billion by 2034, indicating significant growth potential for innovative treatments [7]

WESTON, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, has issued a Shareholder Letter addressing R&D trends for inflammasome inhibitors in development, and provides an update on the develop ...